Tolerability and Pharmacokinetics Following a Single Dose of Vardenafil in Healthy Korean Volunteers

Seokuee Kim; SeungHwan Lee; Kyoung Soo Lim; Hyeong-Seok Lim; Sang-Goo Shin; In-Jin Jang; Kyung-Sang Yu

doi:10.0000/jkscpt.2012.20.2.125

Journal List > J Korean Soc Clin Pharmacol Ther > v.20(2) > 1055103

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim, Lee, Lim, Lim, Shin, Jang, and Yu: Tolerability and Pharmacokinetics Following a Single Dose of Vardenafil in Healthy Korean Volunteers

Original Article

Journal of Korean Society for Clinical Pharmacology and Therapeutics

Journal of Korean Society for Clinical Pharmacology and Therapeutics 2012; 20(2): 125-134.

Published online: 31 December 2012

DOI: https://doi.org/10.0000/jkscpt.2012.20.2.125

Tolerability and Pharmacokinetics Following a Single Dose of Vardenafil in Healthy Korean Volunteers

Seokuee Kim¹, SeungHwan Lee¹, Kyoung Soo Lim¹, Hyeong-Seok Lim², Sang-Goo Shin¹, In-Jin Jang¹, Kyung-Sang Yu¹

¹Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea.

²Department of Clinical Pharmacology and Therapeutics, University of Ulsan and Asan Medical Center, Seoul, South Korea.

Corresponding author (ksyu@snu.ac.kr)

Received 21 June 2012 Revised 1 December 2012 Accepted 5 December 2012

Abstract

Background

Vardenafil is a phosphodiesterase type 5 inhibitor, used in erectile dysfunction. This study aimed to evaluate the pharmacokinetics and tolerability of vardenafil following a single oral administration in healthy male subjects.

Methods

A randomized, double-blind, placebo-controlled, single dosing, dose-escalation study was conducted in 30 healthy subjects. A single oral dose of vardenafil or placebo was given to 10 subjects (8 active + 2 placebo) in each dose group of 5, 10 and 20 mg. Serial blood and urine samples were obtained up to 48 hours for pharmacokinetic analysis. Vardenafil and its metabolite were detected by high performance liquid chromatography tandem mass spectrometry assay.

Results

A total of 45 adverse events (AE) were reported in 22 subjects, including 5 AEs from placebo treatment, and all the AEs were mild, except one case of moderate nasal stuffiness. Vardenafil was absorbed after a single oral dose, with the t_max of 0.5-1.0 hours. The C_max and AUC_last were 10.21 ± 3.68 ug/L(mean ± SD) and 18.08 ± 7.44 ug×h/L in 5 mg dose group, 19.79 ± 12.13 ug/L and 38.61 ± 21.04 ug×h/L in 10 mg dose group and 53.16 ± 37.01 ug/L and 110.05 ± 69.65 ug×h/L in 20 mg dose group. Dose-linearity on AUC_last and C_max of vardenafil were observed in three dose groups. In all dose groups, the fraction excreted in urine was less than 1%.

Conclusion

The vardenafil was tolerable over a single dose range of 5 - 20 mg. The pharmacokinetics of vardenfil after a single oral dose was explored and linear pharmacokinetic characteristics were observed over the dose range of 5 - 20 mg in healthy subjects.

Keywords: Vardenafil, Phosphodiesterase 5 inhibitor, Pharmacokinetics, Safety

Figures and Tables

Figure 1

Chemical structure of vardenafil andits metabolite N-desethylvardenafil.

Figure 2

Mean (arithmetic mean) - SD plasma concentration-time profiles of (a) vardenafil and (b) N-desethyl vardenafil in log scale after a single oral administration of vardenafil 5 mg, 10 mg and 20 mg. Error bars represent standard deviations.

Figure 3

Dose-normalized C_max and AUC_last after a single oral administration of vardenafil 5 mg, 10 mg and 20 mg. The box defines the upper quartile and lower quartile, and encloses 50% of the data. The median is depicted as a line with in the box. ((a): Dose-normalized C_max, (b): dose-normalized AUC_last).

Figure 4

Metabolic ratio between vardenafil and N-desethyl vardenafil after a single oral administration of vardenafil 5 mg, 10 mg and 20 mg. The box defines the upper quartile and lower quartile, and encloses 50% of the data. The median is depicted as a line with in the box.

Table 1

Demographic data of subjects

^*Data are presented as mean ± standard deviation. ^*Kruskal-Wallis test.

Table 2

Pharmacokinetic parameters of vardenafil and N-desethyl vardenafil after oral administratioin of vardenafil

All data presented as arithmetic mean ± standard deviation except t_max. ^*Data presented as median (range). t_max: Time of maximum observed plasma concentration. C_max: Maximum observed plasma concentration. AUC_last: Areaunder the plasma concentration-time curve from zero time until the last measurable concentration. CL/F: Apparent clearance. t_1/2: Termin alelimination half-life. Ae_0-48h: Total Amount of unchanged drug excreted into the urine within time span 0 to 48h. fe/Fe: Fraction of the non-intravenously administered drug excreted into the urine. CL_R: Renal clearance of the drug from plasma.

Table 3

Assessment of dose-proportionality for pharmacokinetics of vardenafil

Y = a + b × Dose, Y: parameter (C_max, AUC_last). Ln Y=a + b × ln(Dose), Y: parameter (C_max, AUC_last). ANOVA: Analysis of variance.

References

1. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, de Tejada IS, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2004. 1(1):6–23.

2. Albersen M, Orabi H, Lue TF. Evaluation and treatment of erectile dysfunction in the aging male: a mini-review. Gerontology. 2012. 58(1):3–14.

3. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010. 57(5):804–814.

4. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007. 120(2):151–157.

5. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005. 294(23):2996–3002.

6. Cho BL, Kim YS, Choi YS, Hong MH, Seo HG, Lee SY, Shin HC, Kim CH, Moon YS, Cha HS, Kim BS. Prevalence and risk factors for erectile dysfunction in primary care: results of a Korean study. Int J Impot Res. 2003. 15(5):323–328.

7. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994. 151(1):54–61.

8. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol. 2005. 45(9):987–1003.

9. Research CfDEa. NDA 021400 Levitra (Vardenafil Hydrochloride) Tablets: Clinical Pharmacology/Biopharmaceutics Review. 2003. Rockville, Md: Department of Health and Human Services, US Food and Drug Administration.

10. EMEA. Scientific discussion for the approval of Levitra [Online]. last visited on 27 May 2012.

11. Shon JH, Ku HY, Bae SY, Oh MK, Yeo CW, Bae SK, Shin JG. The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genomics. 2011. 21(12):820–828.

12. Dorne JL, Walton K, Renwick AG. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem Toxicol. 2003. 41(2):201–224.

13. Park SY, Kang YS, Jeong MS, Yoon HK, Han KO. Frequencies of CYP3A5 genotypes and haplotypes in a Korean population. J Clin Pharm Ther. 2008. 33(1):61–65.

14. Choi MK, Song IS. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil. J Pharm Pharmacol. 2012. 64(8):1074–1083.

TOOLS

Similar articles